Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan

Next Previous
Trial Profile

A Phase 3b, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Participants With Generalized Myasthenia Gravis Switching From Intravenous Complement Component 5 Inhibitors to Subcutaneous Zilucoplan

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zilucoplan (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Registrational
  • Sponsors UCB Biopharma

Most Recent Events

  • 29 Oct 2025 According to an UCB media release, company will present data from this trial at the 2025 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session, taking place between October 29 and November 1, 2025, in San Francisco.
  • 13 May 2025 According to an UCB media release, Data from this study will be presented at the Myasthenia Gravis Foundation of America (MGFA) International Conference taking place May 13-15, 2025, at The Hague, The Netherlands.
  • 03 Apr 2025 According to an UCB media release, According to an UCB media release, According to UCB media release, data from this study will be presented at American Academy of Neurology (AAN) meeting, San Diego California, April 5- 9, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top